Dr Simon Lord

  • BM BS FRCP DPhil
  • Medical Oncology

Overview

Awards received

  • 2006 Walport Academic Clinical Fellowship, St James Hospital, Leeds
  • 2010 CRUK Clinical DPhil Studentship, University of Oxford
  • 2014 Association of Cancer Physicians McElwain Prize
  • 2014 NCRI prize award
  • 2018 Oriel College Against Breast Cancer Research Fellow
  • 2019 Fellowship of Royal College of Physicians

Clinical interests

Dr Simon Lord has a clincal interest in breast cancer and clinical trials of novel agents for the treatment of breast cancer

Publications

  • Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. Br J Cancer. 2020 Jan;122(2):258-265
  • Window of opportunity clinical trial designs to study cancer metabolism. Br J Cancer. 2020 Jan;122(1):45-51
  • Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. Eur J Cancer. 2020 Jan;122(1):45-51
  • Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019 Aug;20(8):1124-1135
  • Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. PNAS. 2019 Jun;116(25):12452-12461
  • Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer. Cell Metabolism. 2018 Nov;28(5):679-688

Dr Simon Lord's reviews